全文获取类型
收费全文 | 529篇 |
免费 | 44篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 18篇 |
妇产科学 | 26篇 |
基础医学 | 52篇 |
口腔科学 | 1篇 |
临床医学 | 61篇 |
内科学 | 110篇 |
皮肤病学 | 2篇 |
神经病学 | 24篇 |
特种医学 | 48篇 |
外科学 | 123篇 |
综合类 | 3篇 |
预防医学 | 24篇 |
眼科学 | 7篇 |
药学 | 18篇 |
中国医学 | 2篇 |
肿瘤学 | 48篇 |
出版年
2023年 | 8篇 |
2022年 | 5篇 |
2021年 | 12篇 |
2020年 | 15篇 |
2019年 | 9篇 |
2018年 | 12篇 |
2017年 | 20篇 |
2016年 | 8篇 |
2015年 | 17篇 |
2014年 | 30篇 |
2013年 | 31篇 |
2012年 | 35篇 |
2011年 | 31篇 |
2010年 | 23篇 |
2009年 | 9篇 |
2008年 | 32篇 |
2007年 | 28篇 |
2006年 | 33篇 |
2005年 | 27篇 |
2004年 | 13篇 |
2003年 | 25篇 |
2002年 | 25篇 |
2001年 | 18篇 |
2000年 | 15篇 |
1999年 | 12篇 |
1998年 | 8篇 |
1997年 | 5篇 |
1996年 | 3篇 |
1995年 | 2篇 |
1994年 | 1篇 |
1992年 | 4篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 8篇 |
1988年 | 3篇 |
1987年 | 3篇 |
1986年 | 7篇 |
1985年 | 9篇 |
1984年 | 7篇 |
1983年 | 6篇 |
1977年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有573条查询结果,搜索用时 171 毫秒
1.
2.
3.
4.
5.
Expression of collagen, interstitial collagenase, and tissue inhibitor of metalloproteinases-1 in restenosis after carotid endarterectomy. 总被引:3,自引:2,他引:3 下载免费PDF全文
S. T. Nikkari R. L. Geary T. Hatsukami M. Ferguson R. Forough C. E. Alpers A. W. Clowes 《The American journal of pathology》1996,148(3):777-783
Extracellular matrix is the principal component of the fibrous caps of atherosclerotic plaques and intimal hyperplastic lesions of reconstructed arteries. Interstitial collagen form an important part of the matrix, and the balance between collagen synthesis and degradation by interstitial collagenase (matrix metalloproteinase-1, MMP-1) may determine whether plaques rupture or vessels develop stenosis. We examined type I procollagen gene expression in human atherosclerotic and restenotic carotid arteries using in situ messenger RNA (mRNA) hybridization and the expression of MMP-1 and its endogenous inhibitor (tissue inhibitor of metalloproteinases-1, TIMP-1) by immunohistochemistry. Compared with normal arteries, atherosclerotic plaques bed increased expression of immunoreactive MMP-1 and TIMP-1 with modest increase of type 1 procollagen mRNA. Early restenotic lesions (< 1.5 years) contained abundant type I procollagen mRNA but little immunoreactive MMP-1 and TIMP-1. Late restenotic lesions (> 4 years) resembled atheroma and exhibited increased immunoreactive MMP-1 and TIMP-1 as well as abundant type I procollagen mRNA. Compared with atherosclerotic plaques, type I procollagen is increased and MMP-1 is decreased in early restenotic lesions. MMP-1 and TIMP-1 expressions are upregulated in lesions with a clear atheroma. These findings suggest that the balance between proteolysis and matrix synthesis may influence both the stability of atheromatous plaques and the development of restenotic lesions. 相似文献
6.
Sarah Wang Lina Patel Elise A. Sannar Mellad Khoshnood Natalie K. Boyd Lorena Mendez Noemi A. Spinazzi Eileen A. Quinn Michael S. Rafii Jonathan D. Santoro 《American journal of medical genetics. Part A》2023,191(7):1769-1782
Down syndrome regression disorder (DSRD) is a clinical symptom cluster of acute or subacute neurocognitive regression in otherwise health persons with Down syndrome. The objective of this study was to evaluate if adverse childhood experiences (ACEs) were more prevalent in children with DSRD than those with DS alone. A survey-based, cohort-based study was performed. Caregivers of individuals with DSRD with onset of symptoms between age 10 and 30 years and DS alone were administered the ACEs questionnaire via an online REDCap survey. A total of 159 responses were collected after excluding incomplete surveys and those not meeting criteria for DSRD. Individuals with DSRD were not more likely to experience ACEs (p = 0.18, 95% confidence interval [CI]: 0.43–1.17). In those with ACEs prior to the onset of symptoms, the median time prior was 7 months (interquartile range: 5–10). Individuals with DSRD were more likely to report three or more ACEs (52, 33%) compared to those with DS alone (39, 22%) (p = 0.02, 95% CI: 1.08–2.87). Exposure to ACEs were not predictive of response to particular therapeutic interventions although those with multiple ACEs 3 months prior to the onset of symptoms was associated with lower response rates to benzodiazepines and immunotherapy (p = 0.02, 95% CI: −3.64–−1.13). This study provides preliminary data that individuals with DSRD experience ACEs at a similar rate to individuals with only DS alone, although three or more ACEs, often preceding the onset of symptoms, was more prevalent in individuals with DSRD. 相似文献
7.
8.
Z Zhu K Hattori H Zhang X Jimenez D L Ludwig S Dias P Kussie H Koo H J Kim D Lu M Liu R Tejada M Friedrich P Bohlen L Witte S Rafii 《Leukemia》2003,17(3):604-611
Vascular endothelial growth factor (VEGF) and its receptors (VEGFR) have been implicated in promoting solid tumor growth and metastasis via stimulating tumor-associated angiogenesis. We recently showed that certain 'liquid' tumors such as leukemia not only produce VEGF, but also express functional VEGFR, resulting in an autocrine loop for tumor growth and propagation. A chimeric anti-VEGFR2 (or kinase insert domain-containing receptor, KDR) antibody, IMC-1C11, was shown to be able to inhibit VEGF-induced proliferation of human leukemia cells in vitro, and to prolong survival of nonobese diabetic-severe combined immune deficient (NOD-SCID) mice inoculated with human leukemia cells. Here we produced two fully human anti-KDR antibodies (IgG1), IMC-2C6 and IMC-1121, from Fab fragments originally isolated from a large antibody phage display library. These antibodies bind specifically to KDR with high affinities: 50 and 200 pM for IMC-1121 and IMC-2C6, respectively, as compared to 270 pM for IMC-1C11. Like IMC-1C11, both human antibodies block VEGF/KDR interaction with an IC(50) of approximately 1 nM, but IMC-1121 is a more potent inhibitor to VEGF-stimulated proliferation of human endothelial cells. These anti-KDR antibodies strongly inhibited VEGF-induced migration of human leukemia cells in vitro, and when administered in vivo, significantly prolonged survival of NOD-SCID mice inoculated with human leukemia cells. It is noteworthy that the mice treated with antibody of the highest affinity, IMC-1121, survived the longest period of time, followed by mice treated with IMC-2C6 and IMC-1C11. Taken together, our data suggest that anti-KDR antibodies may have broad applications in the treatment of both solid tumors and leukemia. It further underscores the efforts to identify antibodies of high affinity for enhanced antiangiogenic and antitumor activities. 相似文献
9.
10.